57 results about "CMV Pneumonia" patented technology

The invention relates to the technical field of biomedicine, in particular to a primer probe combination for broad-spectrum screening of common respiratory pathogens and application of the primer probe combination. Through screening and optimization, the respiratory pathogen nucleic acid detection primer probe combination for broad-spectrum screening of common acute respiratory infection and community-acquired pneumonia is obtained; the primer probe combination covers 18 respiratory tract pathogens, has the advantages of high accuracy, good specificity, strong anti-interference capability, good inclusiveness, high sensitivity, hyperjoint detection and the like, can realize parallel detection of 20 targets in cooperation with totally-closed single-tube PCR amplification, greatly improves early diagnosis of respiratory tract diseases with complex pathogen structures, and has wide application prospects. The method has very important significance on prevention, control and treatment of infectious diseases.

The invention relates to a training method of a respiratory tract infection disease progress and prognosis prediction model. The training method comprises the following steps: extracting mRNA from peripheral blood of a target patient, and carrying out transcriptome sequencing to obtain a sequencing result; based on the ferroptosis related gene set, comparing ferroptosis score differences of two groups of patients with community-acquired pneumonia and sepsis, and screening corresponding ferroptosis related genes with statistical significance from a sequencing result; screening out genes meeting preset conditions from the ferroptosis related genes based on LASSO regression; and establishing an RTI clinical outcome prediction model through logistic regression by taking whether the patient is sepsis or not as an outcome dichotomy variable and taking the screened gene expression quantity as a prediction variable. According to the invention, after the prediction model is subjected to machine learning screening such as LASSO and the like, the core feature with the highest prediction value is reserved, so that the risk of over-fitting of the model on training data is reduced.

The invention discloses application of swertiflavin in preparation of a medicine for treating infectious pneumonia caused by methicillin-resistant staphylococcus aureus, and relates to the technical field of medicine. It is found for the first time that swertiflavin can significantly reduce the toxicity of staphylococcus aureus by inhibiting the activity of ClpP protein in MRSA. In addition, the swertiflavin shows a remarkable protection effect in the treatment of the MRSA infectious pneumonia. Specifically, the swertiflavin not only can relieve the injury degree of lung tissues, but also can reduce infiltration and aggregation of inflammatory cells in the lung. The discovery shows that the swertiflavin has potential application value in the field of anti-infection treatment. The invention provides a novel treatment strategy, namely, swertiflavin is used as an active ingredient for preparing the medicine for treating the staphylococcus aureus infectious pneumonia.

This invention discloses a method for preparing a bivalent inactivated vaccine against bovine Pasteurella multocida type A and B and hemolytic Mansicular disease, belonging to the field of vaccine technology. The invention involves isolating capsular serum Pasteurella multocida type A, Pasteurella multocida type B, and hemolytic Mansicular disease; separately expanding the culture of these bacteria, then inactivating and concentrating the bacterial suspensions, and resuspending them in PBS to prepare bacterial suspensions; and finally, mixing the Pasteurella multocida type A, Pasteurella multocida type B, and hemolytic Mansicular disease suspensions with aluminum hydroxide adjuvant to prepare the inactivated vaccine. This invention provides simultaneous prevention of two diseases—bovine fibrinous purulent pneumonia and bovine hemorrhagic septicemia—as well as bovine Mansicular disease through vaccine immunization. The vaccine demonstrates good safety, stable immunization efficacy, and a long duration of immunity.

This invention discloses a device and its application for distinguishing between pneumonia and tuberculosis in children. By detecting S100A8 / A9 and determining the corresponding diagnostic threshold, this invention achieves rapid, sensitive, and specific differentiation between children with tuberculosis and normal children, as well as children with pneumonia caused by other pathogens. It provides a reliable basis for clinical auxiliary diagnosis, improves diagnostic efficiency and accuracy, avoids misdiagnosis and missed diagnosis, and can thus guide rational clinical treatment and improve patient prognosis.

The application discloses a digital image quantitative dual-mode detection system and method based on a cascade enhanced nano-enzyme, which comprises a probe prepared from a membrane nano-enzyme material, an immunochromatography test strip and a signal automatic analysis system, the nano-enzyme material takes molybdenum disulfide nanosheets as a substrate, sequentially loads large-diameter platinum-iridium alloy particles and small-diameter platinum-iridium alloy particles through polyethylene imine-mediated electrostatic self-assembly, and forms a high-density catalytic active site array. The probe is coupled with specific antibodies on the surface of the nano-enzyme material. Based on the inherent light absorption and peroxidase-like activity of the probe, a dual-mode detection strategy of physical color development-catalytic enhancement is established, high-concentration sample visual preliminary screening and low-concentration sample ultra-sensitive quantitative detection are realized, and combined with an adaptive cross-peak colorimetric quantitative algorithm, individual visual perception differences can be effectively eliminated, and on-site rapid quantitative screening of community-acquired pneumonia pathogens such as streptococcus pneumoniae and legionella pneumophila can be realized.

The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA / DNA) or variants thereof.

The application discloses application of an aloe oral liquid in preparation of a medicine for treating acute viral pneumonia. A preparation method of the aloe oral liquid comprises the following steps: after fresh aloe leaves are washed and peeled, the fresh aloe leaves are scraped to prepare fresh aloe gel; the fresh aloe gel liquid is placed in a light reaction tank, and is subjected to blue light, red light and no light alternately under low-temperature conditions; the fresh aloe gel after light treatment is pumped into a decocting and concentrating tank, and is concentrated to a supernatant with a density of 1.10 kg / m 3 1.2 kg / m 3 between, is filled and sealed after cooling, and is sterilized to obtain the aloe oral liquid. The application promotes clinical indications of fresh aloe leaves, provides a new drug selection for clinical treatment of acute viral pneumonia, provides a technical reference for industrial production of fresh aloe leaf medicine products, and promotes inheritance and innovation of traditional Chinese medicines with clinical application as a foothold.

The application belongs to the field of intelligent medical treatment, and particularly relates to a method for constructing a refractory mycoplasma pneumoniae pneumonia prediction model and equipment. The method comprises the following steps: acquiring a baseline time data set and a follow-up time label of a mycoplasma pneumoniae patient; inputting the image data set into a lung blood vessel segmentation model to obtain a lung blood vessel network, obtaining a total lung blood vessel volume based on the lung blood vessel network, and obtaining a blood vessel volume of different cross-sectional areas based on a cross-sectional area of the lung blood vessel network; inputting a ratio of the blood vessel volume of different cross-sectional areas to the total lung blood vessel volume into a machine learning model to obtain a prediction label, and obtaining a refractory mycoplasma pneumoniae pneumonia prediction model after iterative optimization of the machine learning model based on a difference between the prediction label and the follow-up time label. The application segments a lung CT image to obtain a blood vessel network diagram, quantitatively obtains a percentage of a blood vessel volume of different thicknesses in a total lung blood vessel volume, and constructs a refractory mycoplasma pneumoniae pneumonia prediction model based on an innovative feature extraction method.

The application discloses a dandelion extract capable of neutralizing bacterial toxins and application thereof. The dandelion extract is mainly prepared by the following method: fresh dandelion juice is squeezed, the juice is collected, the juice is centrifuged, the supernatant is collected, the supernatant is ultra-filtered, and components capable of passing through a filter membrane with a molecular weight cut-off of 100 kD and incapable of passing through a filter membrane with a molecular weight cut-off of 3 kD are collected, namely the dandelion extract. The dandelion extract obtained by the application is natural in composition, free of toxic side effects and high in biological activity. Experimental evidence shows that the dandelion extract can protect host cells from attack by directly and specifically combining with toxins, effectively neutralizes the toxicity of bacterial toxins, and has effective prevention and treatment effects on diseases such as systemic bacterial infection, wound infection and bacterial pneumonia. Therefore, the dandelion extract can be used as a new type of anti-microbial and anti-infection functional material and applied to the fields of functional food, health products, medicines or functional cosmetics.

The application provides a biomarker and application for early detection of aspiration pneumonia. By detecting the biomarker, the defects of the current biomarker for aspiration pneumonia can be overcome, early detection of aspiration pneumonia can be realized, early intervention and preventive measures can be carried out, and the death caused by aspiration pneumonia can be greatly reduced.

The invention discloses an early diagnosis marker for children refractory mycoplasma pneumonia (RMPP) and an RT-qPCR detection method, and relates to the technical field of disease detection. According to the invention, PBMC maps of a healthy control group in the early morbidity stage of RMPP sick children, in the early morbidity stage of mycoplasma pneumoniae pneumonia sick children and in the early morbidity stage of RMPP sick children are drawn for the first time by virtue of an scRNA-seq technology, and IGHM, NEAT1, IL32 and ACTG1 four-gene marker combination for early diagnosis of RMPP in children is innovatively discovered; a peripheral blood sampling scheme is combined to thoroughly solve throat swab sampling obstacles of young children; and a high-precision three-classification diagnosis model is constructed. According to the method disclosed by the invention, the diagnosis time is shortened from 7 days to 24 hours, the sensitivity is improved to 93-96%, the detection cost is reduced by 95%, a first molecular solution with high precision, low cost and clinical accessibility is provided for early RMPP intervention of children, and the severe case rate and medical burden are expected to be obviously reduced.

The invention discloses application of a polygonatum odoratum polysaccharide extract in preparation of a medicine for treating viral pneumonia, and belongs to the technical field of medicines. Through experiments, the applicant discovers that the polygonatum odoratum polysaccharide extract can significantly reduce the fluorescence intensity of neutrophils and macrophages in poly (I: C) induced zebrafish viral pneumonia model swimming sacs, has an obvious antiviral effect on zebrafish, can reduce the expression of pro-inflammatory factors tnf alpha, il6 and il12, has an obvious anti-inflammatory effect, and can be used for preparing anti-inflammatory drugs for treating zebrafish viral pneumonia. The compound is expected to be used for preparing anti-viral pneumonia drugs.

The application of CCR2 / CCR5 inhibitor in the preparation of drugs for treating immune checkpoint inhibitor associated pneumonia and products belong to the field of biological medicine technology. The technical problem to be solved is the new application of CCR2 / CCR5 inhibitor in the preparation of drugs for treating pneumonia, and the treatment effect of immune checkpoint inhibitor associated pneumonia is better than that of single inhibitor. The technical solution is the application of CCR2 / CCR5 inhibitor in the preparation of drugs for treating pneumonia.

The application discloses a drug delivery system targeting lung alveolus microenvironment oxidation and reduction as well as a preparation method and application thereof, and comprises nanoparticles self-assembled by amphiphilic GSH-(oxi)PEI-PCL polymers, wherein the nanoparticles load fat-soluble drugs or fluorescent dyes, GSH in the amphiphilic GSH-(oxi)PEI-PCL polymers is connected with (oxi)PEI-PCL through a disulfide bond, and the (oxi)PEI-PCL is PEI-PCL subjected to partial oxidation. The pharmacodynamic test result shows that the drug delivery system can realize passive targeting aggregation of drugs in a lesion and microenvironment oxidation and reduction sensitive distribution, meanwhile, the drug delivery system shows an antioxidation effect in a lesion microenvironment and intracellular, realizes more accurate drug distribution effect and in-vivo treatment effect, and provides a new drug route for treatment of lung diseases such as premature lung dysplasia, bacterial / viral pneumonia or burn inhalation lung injury.

The invention belongs to the technical field of preparation of peptides, and particularly relates to a spirulina peptide, a preparation method, a product and application. The invention provides a spirulina peptide. The spirulina peptide comprises a first algae peptide, a second algae peptide, a third algae peptide, a fourth algae peptide and a fifth algae peptide. According to the preparation method of the spirulina peptide provided by the technical scheme, the neutral protease can preliminarily decompose protein in spirulina, the binding structure of the protein and polysaccharide is destroyed, and macromolecular protein is decomposed into medium-sized peptide fragments. Alkaline protease can deeply hydrolyze protein to generate the antiviral pneumonia active peptide with biological activity. And the papain can accurately regulate and control the molecular weight of the peptide fragment, so that the generated peptide fragment has relatively high water solubility and emulsifying activity, and the antiviral effect is high. Results of embodiments show that the spirulina peptide provided by the invention has the efficacy of resisting viral pneumonia.

This invention provides an antibacterial and anti-adhesion double-balloon tracheostomy cannula and its preparation method. The invention involves constructing a coating material co-loaded with a newly developed tetradecyl antibacterial agent and chondroitin sulfate on both the cannula's surface and inner wall. This coating possesses both excellent hydrophilicity and strong antibacterial properties. The hydrophilicity makes it difficult for secretions to adhere; the antibacterial properties kill bacteria through contact, minimizing the development of drug resistance; and the anti-adhesion properties reduce the basis for biofilm formation. These three properties work synergistically to achieve full-chain protection from the "source" to the "process," significantly reducing the risk of luminal obstruction and VAP (ventilator-associated pneumonia), while also reducing the frequency of suctioning and mucosal damage, thus improving patient comfort.

The application discloses application of chelerythrine combined with polymyxin E in inhibition of polymyxin E drug-resistant bacteria, and the polymyxin E drug-resistant bacteria are mcr positive bacteria. Experiments prove that chelerythrine can inhibit (such as mcr-1 positive escherichia coli ZJ807, mcr-8 positive klebsiella pneumoniae KP91 and mcr-9 positive salmonella SLM183) in cooperation with polymyxin E, and can reduce the use amount of polymyxin E and reverse the drug resistance to polymyxin E. Chelerythrine can restore the inhibitory effect of polymyxin E on the polymyxin E drug-resistant bacteria. The application has important application value.

The invention discloses an application of an aloe oral liquid in preparation of a medicine for treating acute viral pneumonia. The preparation method of the aloe oral liquid comprises the following steps: cleaning and peeling fresh aloe leaves, and scraping to prepare fresh aloe gel; putting the fresh aloe gel liquid into an illumination reaction tank, and carrying out blue light, red light and dark alternate treatment under a low-temperature condition; pumping the fresh aloe gel subjected to illumination treatment into a decoction concentration tank, concentrating until the liquid medicine is clear liquid with the density of 1.10 kg / m < 3 > to 1.2 kg / m < 3 >, cooling, filling, sealing and sterilizing to obtain the aloe gel. Clinical indications of the fresh aloe leaves are promoted, a new medication choice is provided for clinical treatment of acute viral pneumonia, technical reference is provided for industrial production of fresh aloe leaf medicine products, and traditional Chinese medicine inheritance and innovation with clinical application as a foothold are promoted.

The invention belongs to the technical field of microorganisms, and particularly relates to rabbit source D-type pasteurella multocida and application thereof. The preservation number of the strain is CCTCC (China Center For Type Culture Collection) NO: M 2024856. The strain induces cellulosic pneumonia, has an application value of constructing a rabbit pasteurellosis animal model, and has good immunogenicity, a whole-cell inactivated antigen can effectively stimulate immune response of a mouse body and induce generation of a high-level antibody, and the strain has the potential of being developed into a vaccine.

The invention discloses a drug delivery system targeting alveolar microenvironment redox and a preparation method and application thereof.The drug delivery system comprises nanoparticles formed by self-assembly of an amphiphilic GSH-(oxi) PEI-PCL polymer, fat-soluble drugs or fluorescent dyes are loaded in the nanoparticles, GSH and (oxi) PEI-PCL in the amphiphilic GSH-(oxi) PEI-PCL polymer are connected through a disulfide bond, and the lipid-soluble drugs or fluorescent dyes are loaded in the nanoparticles. And the (oxi) PEI-PCL is the PEI-PCL subjected to partial oxidation. Pharmacodynamic test results show that the drug delivery system provided by the invention can realize passive targeting aggregation in a focus and microenvironment redox sensitive distribution of the drug, simultaneously shows antioxidant effects in the focus microenvironment and cells, realizes a relatively exact drug distribution effect and an in-vivo treatment effect, and has a wide application prospect. The invention provides a new drug approach for the treatment of lung diseases such as premature lung dysplasia, bacterial / viral pneumonia or burn inhalation lung injury and the like.

The present application relates to the technical field of pharmaceutical formulations, and in particular, to an astragaloside IV liposome for treating viral pneumonia and a preparation method therefor. The astragaloside IV liposome for treating viral pneumonia comprises: astragaloside IV and a liposome loaded with astragaloside IV. The liposome comprises lecithin, cholesterol, and distearoylphosphatidylethanolamine-polyethylene glycol. The liposome provided by the present application efficiently encapsulates astragaloside IV to enhance its stability. Animal model experiments demonstrate that the astragaloside IV liposome of the present application can mitigate viral pneumonia-induced lung damage and significantly boost the survival rate of mice with influenza A viral pneumonia. Thus, the liposome can be well used for treating viral pneumonia caused by influenza A.

The invention provides an application of a serum exosome lncRNA in preparation of a detection product for immune checkpoint inhibitor associated pneumonia, and the serum exosome lncRNA is TTC9-DT, or TTC9-DT and ITGA2-AS1. The invention also provides an application of the serum exosome lncRNA in preparation of a detection product for immune checkpoint inhibitor associated pneumonia. By using the serum exosome lncRNA disclosed by the invention, the sensitivity, the specificity and the accuracy of immune checkpoint inhibitor-related pneumonia diagnosis can be remarkably improved, and compared with a clinical conventional non-specific blood index, the serum exosome lncRNA disclosed by the invention has a better diagnosis effect. In addition, detection can be carried out in a liquid biopsy mode, the method has the advantages of being minimally invasive, capable of achieving real-time monitoring and the like, a detection reagent is low in cost and high in universality, efficient clinical diagnosis and identification can be carried out, the early diagnosis rate is increased, and the method has high clinical application value and wide application prospects.

This invention discloses the application of duracil in the preparation of drugs for treating infectious pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA), relating to the field of pharmaceutical technology. This invention is the first to discover that duracil can significantly reduce the virulence of Staphylococcus aureus by inhibiting the activity of the ClpP protein in MRSA. Furthermore, duracil exhibits significant protective effects in the treatment of MRSA-induced infectious pneumonia. Specifically, duracil not only reduces the degree of lung tissue damage but also reduces the infiltration and aggregation of inflammatory cells in the lungs. These findings indicate that duracil has potential application value in the field of anti-infective therapy. This invention provides a novel therapeutic strategy, namely, using duracil as the active ingredient in the preparation of drugs for treating Staphylococcus aureus-induced infectious pneumonia.

The invention belongs to the technical field of medicine. The invention discloses an application of forsythiaside A in preparation of a medicine for treating bacterial infectious pneumonia. The method comprises the following steps: firstly, establishing a model of mice bacterial infectious pneumonia caused by tracheal intubation instillation of Pseudomonas aeruginosa in vivo, and applying forsythiaside A to treat, so that the infection symptom of the model mice can be obviously relieved, and the lung inflammatory response can be effectively relieved. The method comprises the following steps: firstly, establishing a model of pulmonary alveolar macrophages infected with Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii in vitro, and then, establishing a model of pulmonary alveolar macrophages infected with Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii in vitro, so that after forsythiaside A is added, the damage of the macrophages can be effectively alleviated, and the number of infectious bacteria in cytoplasm can be reduced. Experimental results show that forsythiaside A can be effectively used for treating bacterial infectious pneumonia.

This invention belongs to the field of medical auxiliary prediction model construction technology. Current prediction models for refractory Mycoplasma pneumoniae pneumonia are all multimodal and rely on time-consuming experimental results, making them unsuitable for the clinical need to quickly determine the probability of having refractory Mycoplasma pneumoniae pneumonia. This invention proposes a method, device, medium, and program product for constructing a prediction model for refractory Mycoplasma pneumoniae pneumonia. By developing a Transformer-based deep learning framework, it achieves automated and efficient risk identification of RMPP using baseline non-contrast chest CT without additional examinations. Furthermore, a first prediction model is constructed based on the risk probability values ​​output by the Transformer-based deep learning framework, and a second prediction model is constructed based on the risk probability values ​​and six clinical data points. The predicted probabilities of each model show good consistency with the observed results.

This invention belongs to the field of traditional Chinese medicine application technology and provides an application of a traditional Chinese medicine composition in the treatment of radiation-induced pneumonia. The traditional Chinese medicine composition is made from bamboo sap and *Trifolium repens*; the mass ratio of bamboo sap to *Trifolium repens* is (1-10):(1-10). Radiation-induced pneumonia refers to lung inflammation caused by radiotherapy for malignant tumors of the chest. The traditional Chinese medicine composition provided by this invention has the effects of clearing heat and detoxifying, resolving phlegm and dissipating nodules. It has a simple composition and high safety, providing a new option for the treatment of radiation-induced pneumonia.

The invention provides an early warning method for PD-1 inhibitor immune-related pneumonia, which comprises the following steps: preprocessing acquired multi-omics data, conventional clinical data and CT image data of a PD-1 inhibitor subject to correspondingly obtain a multi-omics feature map, a clinical feature map and a CT image feature tensor; inputting the multiple omics feature maps, the clinical feature maps and the CT image feature tensor into a trained CNN-BNN model for feature extraction and pneumonia prediction to obtain a final disease time and a prediction result of disease probabilities of multiple time windows; and carrying out risk level judgment according to a prediction result, and outputting an early warning report and personalized treatment suggestions. According to the method, multi-dimensional information related to immune pneumonia is comprehensively captured by fusing multi-omics data, conventional clinical data and CT image data, and the accuracy and reliability of prediction are remarkably improved. The model is used for mining complex association in data, the prediction accuracy of the model is improved, and early warning and accurate prediction are realized.

The invention discloses application of polypeptide for inhibiting expression of inflammasome NLRP3 in preparation of pneumonia treatment drugs, and belongs to the technical field of biological medicines. Derived peptide is obtained based on a DTX4 protein functional domain, the peptide fragment is derived from an interaction region of DTX4 and RNA binding protein HuR, and the action mechanism of the peptide fragment is competitive binding with the HuR, so that the stabilizing effect of the HuR on mRNA of various inflammatory factors is blocked, the mRNA is promoted to be degraded, and expression and secretion of the inflammatory factors are inhibited from the level after transcription. The polypeptide disclosed by the invention has the potential of being developed into a novel anti-infectious pneumonia treatment medicine, and a brand new strategy is provided for treating bacterial infectious pneumonia.